N⁶-methyladenosine (m⁶A) is the most abundant modification in eukaryotic messenger RNA. This modification is dynamic, reversible, and mediated by proteins characterized as methyltransferases and demethylases. Recent investigations have found that aberrant expression of methyltransferases and demethylases results in m⁶A dysregulation and, in consequence, affects the biological functions in which this modification is involved. Indeed, m⁶A dysregulation affects the development and maintenance of various diseases, including cancer. For this reason, we explored the potential role that m⁶A modification has in invasive breast cancer of no special type (IBC-NST) and its molecular subtypes luminal A, luminal B HER2-, luminal B HER2+, HER2+, and triple-negative breast cancer (TNBC) whose degree of global m⁶A methylation has not yet been studied.